V181
Biological
Merck Sharp & Dohme Corporation
Total Payments
$2.0M
Transactions
279
Doctors
6
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $16,751 | 6 | 0 |
| 2019 | $462,005 | 115 | 2 |
| 2018 | $1.6M | 156 | 5 |
| 2017 | $17,416 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.0M | 232 | 99.6% |
| Travel and Lodging | $4,485 | 18 | 0.2% |
| Consulting Fee | $3,132 | 3 | 0.2% |
| Food and Beverage | $1,224 | 26 | 0.1% |
Payments by Type
Research
$2.0M
232 transactions
General
$8,841
47 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase I Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Live-Attenuated Tetravalent Dengue Vaccine V181 in Flavivirus-Na ve and Flavivirus-Experienced Healthy Adults | Merck Sharp & Dohme Corporation | $2.0M | 0 |
Top Doctors Receiving Payments for V181
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Juan, PR | $2.0M | 232 |
| , MD | Internal Medicine | Syracuse, NY | $2,132 | 2 |
| , M.D | Pulmonary Disease | San Antonio, TX | $1,898 | 13 |
| , MD | Adolescent Medicine | Galveston, TX | $1,337 | 11 |
| , MD | Family Medicine | Rochester, NY | $1,258 | 10 |
| , MD | Research Data Abstracter/Coder | San Juan, PR | $1,216 | 10 |
| , M.D | Infectious Disease | Baltimore, MD | $1,000 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $2.0M
- Total Doctors 6
- Transactions 279
About V181
V181 is a biological associated with $2.0M in payments to 6 healthcare providers, recorded across 279 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $16,751 was paid across 6 transactions to 0 doctors.
The most common payment nature for V181 is "Unspecified" ($2.0M, 99.6% of total).
V181 is associated with 1 research study, including "A Phase I Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Live-Attenuated Tetravalent Dengue Vaccine V181 in Flavivirus-Na ve and Flavivirus-Experienced Healthy Adults" ($2.0M).